VolitionRx expects final colorectal test results early next year
Initial results from the use of its NuQ test were encouraging.
Company
NYSE:VNRX
VolitionRx Limited is a multi-national epigenetics company developing simple, easy-to-use, cost-effective blood tests to help diagnose a range of cancers and other diseases. Early diagnosis has the potential to not only prolong the life of patients but also to improve their quality of life. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. Volition is primarily focused on human diagnostics but also has a subsidiary focused on animal diagnostics. Volition's research and development activities are centered in Belgium, with additional offices in Texas, London and Singapore, as the company focuses on bringing its diagnostic products to market.
89 stories · page 5 of 5
Initial results from the use of its NuQ test were encouraging.
Archive
Lots of positive news from the oil sector today from places as far afield as Morocco, Alaska and ... er ... Lincolnshire.
A second study has validated VolitionRx’s NuQ blood test as a way to potentially detect pancreatic cancer..
Results were similar to a completely separate study of 59 individuals at Lund University in Sweden
Shares in VolitionRx rose in early deals after the life sciences company announced it had received a first CE Mark for a blood-based diagnostic assay, paving the way for clinical sales in Europe.
Investments and investor services
It was a busy day in the small cap world with Gemfields garnering much attention...
VolitionRx’s tests are based on the science of Nucleosomics, which identifies and measures nucleosomes in the bloodstream.
Investments and investor services
There was a lot of news to get through today in the world of small caps...
VolitionRx took a step towards commercialising its innovative colorectal cancer tests in the USA........